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Abstract
In early clinical test evaluations the potential benefits of the introduction of a new
technology into the healthcare system are assessed in the challenging situation of limited
available empirical data. The aim of these evaluations is to provide additional evidence
for the decision maker, who is typically a funder or the company developing the test,
to evaluate which technologies should progress to the next stage of evaluation. In this
paper we consider the evaluation of a diagnostic test for patients suffering from Chronic
Obstructive Pulmonary Disease (COPD). We describe the use of graphical models, prior
elicitation and uncertainty analysis to provide the required evidence to allow the test to
progress to the next stage of evaluation. We specifically discuss inferring an influence
diagram from a care pathway and conducting an elicitation exercise to allow specification
of prior distributions over all model parameters. We describe the uncertainty analysis,
via Monte Carlo simulation, which allowed us to demonstrate that the potential value of
the test was robust to uncertainties. This paper provides a case study illustrating how a
careful Bayesian analysis can be used to enhance early clinical test evaluations.
Keywords: Bayesian network; Care pathway analysis; Expert elicitation; Sensitivity
analysis; Uncertainty analysis
1 Introduction
Clinical tests include in vitro tests and medical devices used by healthcare professionals or
patients to support the diagnosis, screening or monitoring of a disease or disease stage. Tests
need to be fully evaluated to assess their benefits and harms to patients and to the healthcare
system before they can be introduced. Evaluations of clinical tests should assess not only the
clinical and economic benefits, but also the potential change in the clinical decision making
process if the test is adopted [Kip et al., 2018, Graziadio et al., 2020]. In the early stages
of evaluation, uncertainty is relatively high and little or no empirical data are available. In
this context, decision analysis, structured prior elicitation and uncertainty analysis within a
Bayesian framework, can provide defensible evidence on the potential benefits and disbenefits
of a clinical test to decision makers.
Clear visualisation of the decision making process may support the test developers and
funders in identifying the role of the test which could maximise the potential benefits of the
test in the healthcare system. Identifying the role of the test is tightly linked to understanding
where the clinical test could fit within the current care pathway. Care pathways are schematic
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visualisations of the journey of a patient in the healthcare system, and care pathway analysis
is the comparison between the current care pathway and the proposed care pathway upon
adoption of the new technology [Charman et al., 2019, Bray et al., 2020]. In health economic
evaluations they are used as preliminary models, established in collaboration with clinicians
and other stakeholders, from which the economic model is extrapolated [Baio and Dawid,
2015, Briggs et al., 2006]. However, methods for robust inference and analysis of care pathways
are still lacking [Chilcott et al., 2010], and the use of formal statistical approaches such as
graphical models (in this case, influence diagrams) and structured expert judgement elicitation
in early stage test evaluation is still relatively immature, although prior elicitation is an
established approach within medical trials more generally [Chaloner and Rhame, 2001, Thall
et al., 2019, Pedroza et al., 2018]. An example of the use of influence diagrams within medical
decision making is given in Owens et al. [1997].
In this case study, the test of interest is a home monitoring test developed by a company
for patients with Chronic Obstructive Pulmonary Disease (COPD). COPD is a chronic res-
piratory condition common in smokers and ex-smokers. There is no cure for patients affected
by COPD but patients can be trained to recognise their symptoms and when they worsen.
Worsening of symptoms can lead to exacerbations that are very unpleasant for the patient
and can often lead to death. COPD is mainly monitored by patients at home but exacer-
bations often necessitate emergency care or consultation with a General Practitioner (GP).
Sometimes patients manage their condition using steroids or antibiotics, but, when a patient
suspects they are having an exacerbation, action can vary, with some patients presenting at
hospital and others allowing symptoms to develop before seeking medical help. We hypoth-
esised that by identifying exacerbations early the number of hospital visits could be reduced
and effective treatment could be administered in the community.
A company has developed a diagnostic test for home monitoring of COPD exacerbations.
It is a urine test that monitors the level of urine biomarkers whose concentrations change when
a patient moves from a stable condition to an exacerbation state. This test could aid patients
in the self-management of their condition. We assumed weekly testing for the monitoring of
their condition. The proposed use of the test is that patients would test themselves when they
feel unwell and are concerned about their clinical symptoms. The test has the potential to
identify whether patients are likely to experience an exacerbation. In this case, the patients
will be prompted to take appropriate action, such as to take steroids or antibiotics or seek
further medical help.
In this paper we consider the early evaluation of the test and its potential to impact the
UK health system. We consider the initial care pathway developed for the test and detail
how this was used to infer an influence diagram. We discuss the formal elicitation process
used to obtain the quantities needed to populate the influence diagram. We describe how
we use these quantities to solve the influence diagram and give an indication of the potential
benefits of the test in the UK healthcare system. We consider the impact of uncertainties
on the evaluation process. We discuss how the elicited quantities were used to form prior
distributions on the model parameters and how they were used to assess the uncertainty on
the key quantities in the analysis. We consider the sensitivity of the main model outputs to
the uncertain model inputs.
Throughout this case study we aim to illustrate the value of cutting-edge methodolog-
ical developments in Bayesian analysis, to aid in uncertainty representation and decision
support, in the context of a real practical problem. We conduct the elicitations using the
state-of-the-art SHeffield ELicitation Framework [Gosling, 2018, Oakley and O’Hagan, 2016,
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OHagan, 2019]. The individual quantitative elicitations are of probabilities which must sum
to one. This has recieved much attention in the recent literature [Wilson, 2018, Elfadaly and
Garthwaite, 2016, Zapata-Va´zquez et al., 2014, Elfadaly and Garthwaite, 2013]. We spec-
ify conditional beta prior distributions for the probabilities as suggested in Wilson [2018],
Elfadaly and Garthwaite [2016]. The translation of qualitative statements into formal graphi-
cal models such as Bayesian networks, in this paper the translation of the care pathway to an
influence diagram, is an important area of current research. Recent work in this area includes
Wilkerson and Smith [2018], Smith [2010], Korb and Nicholson [2009]. Here we adapt the
approach given in Smith [2010].
2 Test evaluation
2.1 Elicitation of the care pathway
We selected 14 health professionals in the field of respiratory healthcare as our experts to
support the development of the care pathway structure, under the guidance of the Academic
Health Sciences Network (AHSN). Experts were selected for their complimentary perspectives
and experience in COPD management, fulfilling the roles of GP, practice nurse, community
matron, respiratory clinician, nurse in a nursing home and service development manager from
the British Lung Foundation, and all had suitable practical knowledge.
The initial structure of the care pathway was inferred through a literature review and a
review of guidelines for COPD management. The care pathway was discussed and its accuracy
assessed by each interviewee through an iterative process until a consensus around the main
structure of the pathway and the causal relationships between the nodes of the pathway was
reached. In total, six iterations were used to establish the final care pathway. The resulting
care pathway represents a high level picture of COPD management that could be considered
common across a wide area of the UK. The final care pathway is given in Figure 1.
The care pathway shows, in the upper section, the monitoring loop of the patient, and, in
the lower section, the possible actions of the patient, primary care professionals and secondary
care professionals1. In the monitoring loop the patient monitors both the symptoms and the
test. An alert can be triggered by a change of symptoms or a positive test result. If only
a positive test result occurs associated with no change of symptoms during baseline testing,
then the test result is not acted on and a re-test is advised. That is, the aim of this early
modelling is to evaluate the test as a diagnostic tool, and excludes monitoring use of the test.
The lower part of the care pathway bifurcates and decisions of different healthcare profes-
sionals are represented in different colours: patient, primary care and secondary care decisions.
With a suspected exacerbation, the patient could decide to wait and potentially retest, to
treat their symptoms or to become service users by contacting their GP, a nurse or presenting
at Accident & Emergency (A&E). The primary care professionals could decide to keep the
patient at home and not treat them, to treat them or to send the patient to a hospital. Upon
physical examination of the patient and in the presence of other diagnostic test results, the
secondary care professionals are able to establish a correct diagnosis of whether an exacerba-
tion is present. As a consequence, they may discharge the patient or admit them to a ward
in the hospital.
1In the UK, National Health Service (NHS) care is provided in two main ways: primary care (GPs and
community services) and secondary care (hospitals and specialists).
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Figure 1: The final version of the care pathway for patients suffering for COPD. A&E stands
for Accident & Emergency.
2.2 Inferring the influence diagram
Influence diagrams are graphical models which support the visualisation and solution of deci-
sion problems. They are an extension of Bayesian networks which incorporate decisions and
utilities in addition to uncertainties. For comprehensive explanations of influence diagrams
see Smith [2010], Howard and Matheson [1981].
The first step to infer an influence diagram from the care pathway is the identification
of the influential variables for the decision of the patients and clinicians involved in the care
pathway. The care pathway facilitated the identification of the problem variables, which
were the decisions of the patient, the primary care professionals and the secondary care
professionals.
We used the approach of Smith [2010], where the most influential variables were identified
working backwards from the outcomes of potential decisions, and gradually identifying the
different layers of uncertainties. We asked the experts to rank the variables to identify those
which were most influential, to be kept in the analysis. There is some evidence that experts are
more reliable in providing rankings than making direct judgements about unknowns [Gosling,
2014]. The rankings from the different groups are omitted but can be found in Graziadio
[2017].
The rankings of the variables helped us to define the layers of uncertainty in the problem,
which can be represented using the trace back graph [Smith, 2010] given in Figure 2. In the
trace back graph, connections between variables do not indicate dependency, but indicate a
partial ordering of how the variables influence each other.
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Figure 2: A trace back graph identifying the variables which are relevant to the decision
making process for the management of COPD patients.
From the discussions with experts, the first layer influencing the actions of the professionals
and the patients was identified as the diagnosis. The experts also identified that their actions
were also conditional on whether in their judgement the patient was able to cope with their
current symptoms and broader condition (e.g. are they panicking? Do they live alone or do
they have support?). However, it was only a minority of interviewees who agreed with this,
and so it was disregarded in the further development of the influence diagram. The main
elements affecting the decisions of the patients and healthcare professionals are elaborated
in the second layer of the graph, and they were identified as the change of symptoms in the
patient and their underlying comorbidities.
In the third layer the variables which were identified as being indirectly informative of a
decision were included. Also, exacerbation presence is included in the third layer, as it cannot
be observed directly by the clinician or the patient, but influences their diagnosis indirectly,
mainly through the change in symptoms. In the fourth layer of uncertainty, the higher level
information influencing the other layers included severity of condition and education level of
the patient, which could influence the cognitive abilities of the patient. The elicitation process
stopped at this point as later variables were not well defined and would not pass a clarity test
[Kjrulff and Madsen, 2013].
The influence diagram (ID) was built using the collated judgements of the experts de-
scribed above. The entry point of the ID is a patient experiencing an increase in symptoms
which causes them concern. The full influence diagram is given in Figure 3.
The decision node is the use of the test, as the decision maker is the funder (or the test
developer). This node influences the diagnosis and actions of the patient and primary care
clinicians, but not the actions of the secondary clinicians. The diagnosis is influenced by the
change of symptoms. Exacerbation presence is not directly observed, and so is a chance node.
The value node is the proportion of hospital admissions. The aim is to evaluate whether
the introduction of the test into the current pathway could reduce the number of hospital
admissions and visits, without increasing the risk of patient harm.
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Figure 3: The complete influence diagram. Green circles are chance nodes, the blue rectangle
is a decision node and the red diamond is a value node. PC is primary care and SC is
secondary care.
In this model, patient management is a high level representation. Only the final choice of
the patient is modelled. The level of detail of this model has been calibrated to the uncertainty
in the current evidence. The Bayesian framework is an advantage here, as the model can be
updated and iterated in the next phase of test evaluation when more evidence is available.
Some of the factors which influence the decisions of patients and healthcare professionals
were, at this early stage of test evaluation, unquantifiable. We used arc reversal techniques to
reduce the ID to a model in which all variables are quantifiable [Shachter, 1988]. The nodes
that we need to remove, which are shaded green in Figure 3, are not barren, as they have
children, and so they need to be made barren before they can be removed.
The easiest node to remove is “Other test results”, as it has only one parent and one
child. Using arc reversal, the edge between “Other test results” and “SC actions” can be
reversed, making the node barren and so it can be removed. “Exacerbation presence” is a
parent of “Other test results”, and so when we remove it “SC action” must inherit it as a
parent. To remove “Change of symptoms” we follow the same procedure to make it barren,
adding an edge between “Exacerbation presence” and “PC diagnosis”, and then between
“Exacerbation presence” and “Patient diagnosis”, to preserve the conditional independence
structure. No cycles were created and independence properties between remaining variables
were not altered. The resulting ID is given in Figure 4.
2.3 Elicitation of expert judgements
In order to assess the possible effect of the introduction of the test on the number of hos-
pital admissions requires populating the influence diagram with probabilities. In light of
the scarcity of empirical data discussed earlier, this can instead be achieved using expert
judgement elicitation.
We used the SHELF method of behavioural expert judgement elicitation and aggregation
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Figure 4: The reduced influence diagram. Green circles are chance nodes, the blue rectangle is
a decision node and the red diamond is a value node. PC is prmary care and SC is secondary
care.
[Oakley and O’Hagan, 2016, O’Hagan et al., 2006] as it offers a robust approach, suitable
for early health technology assessment [Gosling, 2014]. Within the SHELF framework a
considerable amount of preparatory work preceded a workshop with the experts.
Identification of the quantities of interest: The quantities of interest (QoIs) were
the probabilities required to populate the ID. As a result of the edges in the ID, many of
these were conditional probabilities. Some are constrained to 0 or 1. They are all given
in Table 1. We also chose to elicit lower and upper 5% quantiles for these probabilities
to enable a comprehensive uncertainty analysis. The quantities of interest were test adop-
tion (X0 ∈{Yes, No}), the presence of an exacerbation (X1 ∈{Yes, No}), patient diagnosis
(X2 ∈{Exacerbation, No Exacerbation}), patient action (X3 ∈{No Treatment, Treatment,
Primary Care (PC), Secondary Care (SC)}), primary care diagnosis (X4 ∈{Exacerbation,
No Exacerbation}), primary care action (X5 ∈{No Treatment, Treatment, Secondary Care
(SC)}) and secondary care action (X6 ∈{Discharge, Admit}).
Preparation of the evidence dossier: The evidence dossier summarises all quantitative
information relevant to the quantities of interest, and is compiled by the elicitation team and
the experts. In this case there were reports of investigations into COPD in the literature,
data from the test development provided by the company and data on COPD from national
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Decision node X0
X0 = 0 X0 = 1
Using test? Yes No
Prior probabilities for X1
Pr(X1 = 0) Pr(X1 = 1)
X1: Exacerbation presence Yes No
Conditional probabilities for X2
Pr(X2 = 0 |X′ ) Pr(X2 = 1 |X′ )
X2: Patient diagnosis Exacerbation No Exacerbation
Test: Yes Exacerbation: Yes Sensitivity
Test: Yes Exacerbation: No Specificity
Test: No Exacerbation: Yes
X
′
= (X0, X1) Test: No Exacerbation: No
Conditional probabilities for X3
Pr(X3 = 0 |X′′ ) Pr(X3 = 1 |X′′ ) Pr(X3 = 2 |X′′ ) Pr(X3 = 3 |X′′ )
X3: Patient action No treatment Treatment PC SC
Test: Yes Patient: Exacerbation 0
Test: Yes Patient: No Exacerbation 1 0 0 0
Test: No Patient: Exacerbation 0
X
′′
= (X0, X2) Test: No Patient: No Exacerbation 1 0 0 0
Conditional probabilities for X4
Pr(X4 = 0 |X′ ) Pr(X4 = 1 |X′ )
X4: PC diagnosis Exacerbation No Exacerbation
Test: Yes Exacerbation: Yes
Test: Yes Exacerbation: No
Test: No Exacerbation: Yes
X
′
= (X0, X1) Test: No Exacerbation: No
Conditional probabilities for X5
Pr(X5 = 0 |X′′′ ) Pr(X5 = 1 |X′′′ ) Pr(X5 = 2 |X′′′ )
X5: PC action No treatment Treatment SC
Test: Yes Patient Action: PC PC: Exacerbation 0
Test: Yes Patient Action: PC PC: No Exacerbation 1 0 0
Test: No Patient Action: PC PC: Exacerbation 0
X
′′′
= (X0, X3, X4) Test: No Patient Action: PC PC: No Exacerbation 1 0 0
Conditional probabilities for X6
Pr(X6 = 0 |X′′′′ ) Pr(X6 = 1 |X′′′′ )
X6: SC action Discharge Admit
Exacerbation: Yes PC Action: SC Patient Action: PC
Exacerbation: No PC Action: SC Patient Action: PC 1 0
Exacerbation: Yes PC Action: Null Patient Action: SC
X
′′′′
= (X1, X3, X5) Exacerbation: No PC Action: Null Patient Action: SC 1 0
Table 1: The conditional probability tables of the reduced ID. PC stands for primary care and SC stands for secondary care.
databases. Summaries of the information from each of these sources were reported to the
experts in the elicitation.
Identification of the elicitation team: The client for this project is the company. The
roles of co-ordinator, who organises the workshop, and analyst, who displays the resulting
probability distributions to the experts, were fulfilled by one author and the role of advisor,
who helps to clear up misunderstandings between analyst and experts, by the other. The two
authors shared the roles of facilitator, who manages the workshop and recorder, who takes
notes (and an audio recording in this case).
Identification and recruitment of experts: Typically between 4 and 8 experts are
chosen to provide a diversity of experience and knowledge. We chose two experts from those
used to construct the ID to take part in the probability elicitation: the Respiratory Pro-
gramme Lead for the Academic Health Society Network and a GP, Clinical Advisor for New-
castle Hospitals and Senior Partner in a Surgery in Newcastle. All relevant data were shared
between the analyst and the two experts.
Experts’ contribution to the evidence dossier: The experts contributed details of
the Newcastle primary care co-operative COPD audit 2014/15 and data from the quality
and outcomes framework, which collates the information needed for the national reward and
incentives programme for GP surgeries in England. The GP also provided the numbers of
patients in their surgery with COPD and the proportion with additional comorbidities and
mental health issues.
There were then several stages in the workshop itself.
Training of the experts: The experts were trained in subjective probabilities, the
basic structure of influence diagrams and conditional probabilities. The structure of the
ID was validated by the experts. The evidence dossier was discussed in a meeting prior to
the workshop, and the technical training was provided on the day of the elicitation by the
facilitator.
The elicitation session: The main elicitation session was followed by a second meeting
to validate the final ID including probabilities and uncertainty distributions. During the
elicitation, for each QoI, the experts were asked to provide a lower quantile below the median,
the median and an upper quantile above the median. For the lower and upper quantiles they
were asked
“What is the value for the QoI that you would judge it unlikely that the true value is
less/greater than this value?”
For the median they were asked
“What is your best estimate of the QoI?”.
This order was designed to avoid the experts anchoring on the median when choosing
their upper and lower quantiles. The individual judgements were compared and if there was
disagreement the method of the Rational Imaprtial Observer was used to reach a consensus
[Oakley and O’Hagan, 2016]. That is, rather than giving their own judgements, they were
asked to agree on the judgement of a rational observer who is aware of all of the information
and has heard all of the discussions between the experts.
There were two probabilities that the experts were not comfortable giving their proba-
bilities for; the proportion of patients admitted by secondary care clinicians in A&E after
self-referral and after referral from primary care. These quantities were subsequently elicited
from two secondary care respiratory consultants. The resulting medians (“best estimate”)
and upper and lower quantiles from the elicitation are given in Table 2.
The assumption that nobody without an exacerbation would be admitted by secondary
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Decision node X0
X0 = 0 X0 = 1
Using test? Yes No
Prior probabilities for X1
Pr(X1 = 0) Pr(X1 = 1)
Yes No
X1: Exacerbation presence 0.45 (0.4-0.55) 0.55 (0.5-0.6)
Conditional probabilities for X2
Pr(X2 = 0 |X′ ) Pr(X2 = 1 |X′ )
X2: Patient diagnosis Exacerbation No Exacerbation
Test: Yes Exacerbation: Yes 0.9 (0.8-0.97) 0.1 (0.03-0.2)
Test: Yes Exacerbation: No 0.1 (0.03-0.3) 0.9 (0.7-0.97)
Test: No Exacerbation: Yes 0.7 (0.6-0.75) 0.3 (0.25-0.4)
X
′
= (X0, X1) Test: No Exacerbation: No 0.3 (0.25-0.4) 0.7 (0.6-0.75)
Conditional probabilities for X3
Pr(X3 = 0 |X′′ ) Pr(X3 = 1 |X′′ ) Pr(X3 = 2 |X′′ ) Pr(X3 = 3 |X′′ )
X3: Patient action No treatment Treatment PC SC
Test: Yes Patient: Exacerbation 0 0.35 (0.25-0.5) 0.6 (0.4-0.8) 0.05 (0.02-0.15)
Test: Yes Patient: No Exacerbation 1 0 0 0
Test: No Patient: Exacerbation 0 0.15 (0.1-0.2) 0.7 (0.5-0.8) 0.15 (0.1-0.2)
X
′′
= (X0, X2) Test: No Patient: No Exacerbation 1 0 0 0
Conditional probabilities for X4
Pr(X4 = 0 |X′ ) Pr(X4 = 1 |X′ )
X4: PC diagnosis Exacerbation No Exacerbation
Test: Yes Exacerbation: Yes 0.9 (0.8-0.97) 0.1 (0.03-0.2)
Test: Yes Exacerbation: No 0.1 (0.03-0.2) 0.9 (0.8-0.97)
Test: No Exacerbation: Yes 0.7 (0.65-0.8) 0.3 (0.25-0.4)
X
′
= (X0, X1) Test: No Exacerbation: No 0.3 (0.25-0.5) 0.7 (0.5-0.75)
Conditional probabilities for X5
Pr(X5 = 0 |X′′′ ) Pr(X5 = 1 |X′′′ ) Pr(X5 = 2 |X′′′ )
X5: PC action No treatment Treatment SC
Test: Yes Patient Action: PC PC: Exacerbation 0 0.8 (0.6-0.95) 0.2 (0.05-0.4)
Test: Yes Patient Action: PC PC: No Exacerbation 1 0 0
Test: No Patient Action: PC PC: Exacerbation 0 0.85 (0.8-0.9) 0.15 (0.1-0.2)
X
′′′
= (X0, X3, X4) Test: No Patient Action: PC PC: No Exacerbation 1 0 0
Conditional probabilities for X6
Pr(X6 = 0 |X′′′′ ) Pr(X6 = 1 |X′′′′ )
X6: SC action Discharge Admit
Exacerbation: Yes PC Action: SC Patient Action: PC 0.3 (0.05-0.35) 0.7 (0.65-0.95)
Exacerbation: No PC Action: SC Patient Action: PC 1 0
Exacerbation: Yes PC Action: Null Patient Action: SC 0.38 (0.05-0.45) 0.62 (0.55-0.95)
X
′′′′
= (X1, X3, X5) Exacerbation: No PC Action: Null Patient Action: SC 1 0
Table 2: The complete conditional probability tables of the reduced ID. Lower and upper quantiles are given in brackets. PC stands
for primary care and SC stands for secondary care.
care may seem strong. However, secondary care have access to a range of tests and carry
out a more comprehensive assessment of a patient. Therefore, the diagnosis by the secondary
care clinicians is regarded as a gold standard diagnosis.
2.4 Solution to the influence diagram
The aim of the study was to provide the decision maker with some early evidence about the
potential benefits of the test. The test aims to reduce unnecessary hospital admissions, but
not by increasing the risk of missing exacerbations which could lead to a worsening of patient
conditions or death. We reduced the assessment of this aim to three queries:
Query 1 Would the proportion of hospital admissions for patients experiencing a true
exacerbation be reduced, if the test was adopted? To answer this query required comparison
of Pr(X6 = 1 | X0 = 0), the probability of admission to hospital given that the test is adopted
with Pr(X6 = 1 | X0 = 1), the probability of admission to hospital given that the test is not
adopted.
These two probabilities can be calculated based on the structure of the ID. They are
Pr(X6 = 1 | X0 = 0) = Pr(X6 = 1 | X1 = 0, X3 = 2, X5 = 2)Pr(X5 = 2 | X0 = 0, X3 = 2, X4 = 0)
×Pr(X4 = 0 | X0 = 0, X1 = 0)Pr(X3 = 2 | X0 = 0, X2 = 0)
×Pr(X2 = 0 | X0 = 0, X1 = 0)Pr(X1 = 0)
+Pr(X6 = 1 | X1 = 0, X3 = 3)Pr(X3 = 3 | X0 = 0, X2 = 0)
×Pr(X2 = 0 | X0 = 0, X1 = 0)Pr(X1 = 0),
Pr(X6 = 1 | X0 = 1) = Pr(X6 = 1 | X1 = 0, X3 = 2, X5 = 2)Pr(X5 = 2 | X0 = 1, X3 = 2, X4 = 0)
×Pr(X4 = 0 | X0 = 1, X1 = 0)Pr(X3 = 2 | X0 = 1, X2 = 0)
×Pr(X2 = 0 | X0 = 1, X1 = 0)Pr(X1 = 0)
+Pr(X6 = 1 | X1 = 0, X3 = 3)Pr(X3 = 3 | X0 = 1, X2 = 0)
×Pr(X2 = 0 | X0 = 1, X1 = 0)Pr(X1 = 0).
Using the probabilities reported in Table 2, we obtain Pr(X6 = 1 | X0 = 0) = 0.046 and
Pr(X6 = 1 | X0 = 1) = 0.043. This corresponds to a 6.5% potential reduction in necessary
hospital admissions after introduction of the test.
Query 2 Would the proportion of missed exacerbations be reduced, if the test was
adopted? The quantities which can be used to evaluate this are Pr(X5 = 0, X1 = 0 | X0 =
1) + Pr(X3 = 0, X1 = 0 | X0 = 1), the probability that a patient is having an exacerbation
and receives no treatment given that the test is not adopted, and Pr(X5 = 0, X1 = 0 | X0 =
0) + Pr(X3 = 0, X1 = 0 | X0 = 0), the probability that the patient is having an exacerbation
and receives no treatment given that the test is adopted.
The probabilities of missed cases without and with the test are
Pr(X3 or 5 = 0, X1 = 0 | X0 = 1) = Pr(X5 = 0 | X4 = 1, X3 = 2, X0 = 1)Pr(X4 = 1 | X0 = 1, X1 = 0)
×Pr(X3 = 2 | X0 = 1, X2 = 0)Pr(X2 = 0 | X0 = 1, X1 = 0)
×Pr(X1 = 0)
+Pr(X3 = 0 | X0 = 1, X2 = 1)Pr(X2 = 1 | X0 = 1, X1 = 0)
×Pr(X1 = 0),
Pr(X3 or 5 = 0, X1 = 0 | X0 = 0) = Pr(X5 = 0 | X4 = 1, X3 = 2, X0 = 0)Pr(X4 = 1 | X0 = 0, X1 = 0)
×Pr(X3 = 2 | X0 = 0, X2 = 0)Pr(X2 = 0 | X0 = 0, X1 = 0)
×Pr(X1 = 0)
+Pr(X3 = 0 | X0 = 0, X2 = 1)Pr(X2 = 1 | X0 = 0, X1 = 0)
×Pr(X1 = 0).
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Using the probabilities reported in Table 2, we obtain Pr(X3 or 5 = 0, X1 = 0 | X0 = 1) =
0.201 and Pr(X3 or 5 = 0, X1 = 0 | X0 = 0) = 0.069. Thus introduction of the test could
reduce missed cases of true exacerbations by 66%.
Query 3 Would the proportion of unnecessary visits to A&E be reduced, if the test was
adopted? The comparison in this case is between Pr(X5 = 2, X1 = 1 | X0 = 1) + Pr(X3 =
3, X1 = 1 | X0 = 1), the probability that the patient is not having an exacerbation and goes
to hospital conditional on no test and Pr(X5 = 2, X1 = 1 | X0 = 0) + Pr(X3 = 3, X1 = 1 |
X0 = 0), the probability that the patient is not exacerbating and goes to hospital conditional
on test adoption.
The probabilities of unnecessary A&E visits without and with the test are
Pr(X3 or 5 = SC, X1 = 1 | X0 = 1) = Pr(X5 = 2 | X0 = 1, X3 = 2, X4 = 0)Pr(X4 = 0 | X0 = 1, X1 = 1)
×Pr(X3 = 2 | X0 = 1, X2 = 0)Pr(X2 = 0 | X0 = 1, X1 = 1)
×Pr(X1 = 1)
+Pr(X3 = 3 | X0 = 1, X2 = 0)Pr(X2 = 0 | X0 = 1, X1 = 1)
×Pr(X1 = 1),
Pr(X3 or 5 = SC, X1 = 1 | X0 = 0) = Pr(X5 = 2 | X0 = 0, X3 = 2, X4 = 0)Pr(X4 = 0 | X0 = 0, X1 = 1)
×Pr(X3 = 2 | X0 = 0, X2 = 0)Pr(X2 = 0 | X0 = 0, X1 = 1)
×Pr(X1 = 1)
+Pr(X3 = 3 | X0 = 0, X2 = 0)Pr(X2 = 0 | X0 = 0, X1 = 1)
×Pr(X1 = 1).
From the probabilities in Table 2, the probabilities of interest are Pr(X3 or 5 = SC, X1 = 1 |
X0 = 1) = 0.030 and Pr(X3 or 5 = SC, X1 = 1 | X0 = 0) = 0.003. This corresponds to a
potential reduction of unnecessary A&E visits of 90% on adoption of the test.
In the next section, we consider the assessment of the uncertainty in these query proba-
bilities which was conducted in the study.
3 Uncertainty assessment
3.1 Specification of uncertainty distributions
We elicited from the experts three quantiles; the median, a quantile above the median and a
quantile below the median. We take these latter quantiles to be the 5% and 95% quantiles.
We chose to fit a beta distribution to each probability from the experts, as it is relatively
flexible and has support on [0, 1]. For events with more than two categories, for example X3,
a conditional beta distribution structure was used [Wilson, 2018]. That is, beta distributions
represented the probabilities that an individual belonged to particular categories conditional
on their not belonging to any previous category.
Two methods to fit beta distributions from the three quantiles were considered; minimising
the Euclidean distance between the quantiles and the beta distribution and an approach based
on only two elicited quantities from Christensen et al. [2011], which converts the mode and
the 95% quantile directly to values of the beta distribution parameters. The advantage of the
latter method would be a shorter elicitation session, if reliability of the estimation could be
demonstrated.
Consider the first approach. Suppose that the three quantiles elicited from the expert
were
12
(qe(0.05), qe(0.5), qe(0.95)) and the equivalent quantiles for a beta distribution with parame-
ters (a, b) are qa,b(0.05), qa,b(0.5), qa,b(0.95). Then the parameters (a, b) are chosen as
argmina,b
{
[qe(0.05)− qa,b(0.05)]2 + [qe(0.5)− qa,b(0.5)]2 + [qe(0.95)− qa,b(0.95)]2
}
.
In the second approach, suppose that the elicited mode is m. Then the value of a, for any
particular choice of b, can be found as
a =
1 + m(b− 2)
1−m ,
and the value of b is chosen to match qe(0.95) in combination with this value of a.
We note that we regard the best estimate as the median and mode respectively in these
approaches. While some of the distributions were relatively asymmetric, in most of the fitted
distributions the mode and median were relatively close to eachother.
An alternative to the second approach would be to use the mode and 5% quantile. We
chose to use the 95% quantile as we feel it is perhaps easier for an expert to think about the
journey of “most” patients rather than a small proportion of patients.
The methods were compared based on the query probabilities from the previous section.
Once each beta distribution on the input probabilities was defined using either method, a
Monte Carlo simulation was conducted to obtain a sample of size 200,000 from each query
probability. From this empirical distribution on each model output, we extracted the mean,
median, mode, standard deviation and the 95% implied probability interval. The probability
intervals were calculated in two ways: using the empirical distribution from the Monte Carlo
sample and assuming a beta distribution for the query probability with parameters a =
x¯[x¯(1− x¯)/s2 − 1] and b = (1− x¯)[x¯(1− x¯)/s2 − 1], where (x¯, s) were the mean and standard
deviation from the sample.
Table 3 provides the comparison based on the probability intervals.
There are differences between the resulting beta distributions when based on the two- or
three-point estimates. We considered the difference between the median estimated from the
simulation and that calculated exactly using the ID. The squared difference between these two
quantities were (0.001, 0.001, 0.000) for the three point estimate and (0.003, 0.001, 0.0002) for
the two-point estimate in the case of no test and (0.000, 0.000, 0.0001) and (0.002, 0.001, 0.0002)
respectively in the case of test adoption. The values from the three-point estimate are con-
sistently lower than the values from the two-point estimate. We see from the table that the
distributions estimated from two quantiles have wider probability intervals than those esti-
mated from three quantiles. The beta distribution assumption looks reasonable based on the
similarity of the implied probability intervals with and without the assumption.
In our assessment of the uncertainty in the query probabilities in the next section we will
provide results based on both the two-point and three-point beta distribution estimates as we
believe the uncertainty inherent in this estimation should be incorporated into the uncertainty
analysis. We will focus the discussion around the three-point estimates as these displayed the
best properties above.
3.2 Assessing query uncertainty
Query 1 The top left plot in Figure 5 provides the densities of the beta distributions under
the no test and test scenarios for the output quantity of query 1, the probability of hospital
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Query 1: Proportion of hospital admissions
3-point estimates 2-point estimates 3-point estimates 2-point estimates
95% PI Beta Empirical Beta Empirical 90% PI Beta Beta
Test (0.018, 0.082) (0.019, 0.082) (0.010, 0.104) (0.011, 0.105) Test (0.021, 0.074) (0.013, 0.092)
No test (0.034, 0.059) (0.034, 0.060) (0.019, 0.079) (0.017, 0.077) No test (0.035, 0.057) (0.022, 0.073)
Query 2: Proportion of missed exacerbations
3-point estimates 2-point estimates 3-point estimates 2-point estimates
95% PI Beta Empirical Beta Empirical 90% PI Beta Beta
Test (0.034, 0.125) (0.034, 0.125) (0.029, 0.138) (0.030, 0.139) Test (0.038, 0115) (0.034, 0.125)
No test (0.166, 0.239) (0.167, 0.239) (0.130, 0.287) (0.131, 0.288) No test (0.172, 0.233) (0.140, 0.272)
Query 3: Proportion of unnecessary A& E visits
3-point estimates 2-point estimates 3-point estimates 2-point estimates
95% PI Beta Empirical Beta Empirical 90% PI Beta Beta
Test (0.001, 0.010) (0.001, 0.010) (0.0001, 0.020) (0.0001, 0.020) Test (0.001, 0.009) (0.0002, 0.016)
No test (0.021, 0.041) (0.021, 0.041) (0.017, 0.048) (0.017, 0.048) No test (0.022, 0.039) (0.019, 0.044)
Table 3: Comparison of implied probability intervals (labelled PI) obtained from the two- and three-point beta distribution estimates.
admission when a patient suspects an exacerbation. There is a large overlap between the
distributions of the proportion of hospital admissions in the current care pathway and the
pathway if the test was introduced. The distribution is more diffuse in the “test” than the
“no test” condition as the experts were more confident specifying probabilities in a clinical
scenario in which they have significant experience.
The 95% probability intervals from the implied distributions for the two conditions show
significant overlap (Table 3) and the 95% probability intervals for the relative risk and odds
ratio comparing the scenarios were (0.518, 2.549) and (0.498, 2.630) respectively, both contain-
ing one. Based on these assessments, the modelling does not provide evidence that hospital
admissions as a result of true exacerbations would decrease on adoption of the test.
Figure 5: Densities of the uncertainty distributions for the queries comparing the current
pathway with the pathway under test adoption. From the top left, clockwise we have query
1, query 2 and query 3.
Query 2 The top right plot in Figure 5 provides the densities of the beta distributions
under the no test and test scenarios for the output quantity of query 2, the probability of
missing an exacerbation when a patient suspects an exacerbation. We see only a very small
overlap between the implied distributions of the proportion of patients who will experience a
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missed exacerbation in the absence or the presence of the test. The adoption of the test is
very likely to reduce the proportion of patients missing exacerbations based on this plot.
The 95% probability intervals (Table 3) for test adoption and no test adoption do not
overlap, supporting the inference from the implied distributions. Similarly, the 95% prob-
ability intervals for the relative risk and the odds ratio are (1.558, 6.089) and (1.689, 7.439)
respectively, with neither containing one, providing further evidence of a difference in the
proportions.
Query 3 The bottom left plot in Figure 5 provides the densities of the beta distributions
under the no test and test scenarios for the output quantity of query 3, the probability of
an unnecessary visit to A&E when a patient suspects an exacerbation. We see essentially
no overlap between the implied distributions for the proportions of unnecessary visits under
adoption and non-adoption of the test, giving evidence that the test is highly likely to reduce
unnecessary A&E visits, even after taking into account our uncertainty.
Again the 95% probability intervals for the implied distributions under “test“ and “no
test“ support this conclusion, as they do not overlap (Table 3), and so do the 95% probability
intervals for the relative risk and the odds ratio, which were (2.708, 44.305) and (2.747, 45.896)
respectively, neither including one.
3.3 Sensitivity analysis
Based on the analysis in the previous section, further investment in test development and
evaluation seems promising. A sensitivity analysis was therefore deemed useful to identify
key uncertainties which it would be helpful to reduce in the next phase of the evaluation. To
do this, we consider the Pearson correlation between the outcome probability for each query,
and each of the input probabilities that query probability depends on. The input probabilities
with the highest correlation with a query probability have the strongest influence on the query
outcome.
The use of correlations to assess the sensitivity of the query probabilities to the input prob-
abilities is relatively simplistic, and more complex approaches such as the expected value of
information in a value of information (VOI) analysis [Jalal and Alarid-Escudero, 2018, Strong
et al., 2014] would improve this aspect of the work. However, this would require information
on costs and effects which are to be collected in the next stage of the test development. Thus
a comprehensive VOI analysis will be conducted then.
We report the results of the sensitivity analysis for query 1. The equivalent outputs for
queries 2 and 3 are omitted, but the main conclusions are given at the end of the section, and
the output can be found in Graziadio [2017].
Figures 6 and 7 show scatterplots of the proportion of hospital admissions against the
simulated values of each of the input probabilities for query 1 from the Monte Carlo sample,
from the no test and adoption of the test scenarios respectively. The input probabilities are
defined in Table 4.
The most influential probability, with an R2 = 0.56, in the no test scenario was p3, the
probability that patients refer to A&E when suspecting an exacerbation. The probabilities
p1 and p6 also had some impact on the distribution of the query probability (R
2 = 0.19 and
R2 = 0.17 respectively). These are the probability that early worsening symptoms evolve into
an exacerbation and the probability that a healthcare professional in primary care refers a
patient with a suspected exacerbation to hospital.
In the situation where the test was adopted, the most influential probabilities were p6 with
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Figure 6: The proportion of hospital admissions plotted against the simulated values of each
of the input probabilities for query 1 from the Monte Carlo sample, for the no test scenario.
R2 = 0.7 and, to a much smaller extent, p3, with R
2 = 0.12. Perhaps surprisingly, the test
sensitivity p2, the probability that the test recognises a true exacerbation, was not strongly
correlated with the probability of hospital admission.
For query 2, the probability of having an exacerbation when some early symptoms appear
(the prevalence) and the probability that patients do not recognise an exacerbation were the
most influential in the no test scenario and in addition the probability that a primary clinician
does not recognise a true exacerbation was influential in the test adoption scenario. These
latter two probabilities both relate to the sensitivity of the diagnosis.
For query 3, the probability that a patient self-refers to A&E on suspicion of an ex-
acerbation and the probability that a patient does not diagnose a true exacerbation were
most influential. This latter probability is again related to the sensitivity of the diagnosis,
indicating that the sensitivity of the test will be a crucial component.
4 Conclusions and discussion
In this paper, we discuss an exhaustive Bayesian approach in the evaluation of a clinical test in
the early phases of development. We took the perspective of the funder/the test developer who
has to decide between investing resources on the next phase of test development or allocating
resources elsewhere. This decision depends on the future budget holder’s decision between
adopting the new clinical test or maintaining the current care pathway. We exploited methods
developed within Bayesian analysis and decision theory to infer the structure of an influence
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Figure 7: The proportion of hospital admissions plotted against the simulated values of each
of the input probabilities for query 1 from the Monte Carlo sample, for the test adoption
scenario.
diagram representing the care pathway, elicit and specify the probabilities to populate and
solve the influence diagram and perform uncertainty and sensitivity analyses on the results.
For statisticians not working in early phase clinical test development, this case study
illustrates some interesting challenges. The first is the need to take into account substantial
uncertainty in the decision making with regards to whether to progress a potential test to more
expensive development phases and what role the test would most usefully fulfill (diagnosis,
monitoring, screening, etc.). The challenge here is that, while some partial data may be
available on the likely performance (sensitivity, specificity, etc.) of the test in ideal lab-
based conditions, and on the behaviour of the patients in the current care pathway, there is
not the comprehensive data necessary for complex statistical modelling, particularly in the
scenario of test adoption. Thus there is an opportunity for subjective Bayesian modelling,
based on expert judgements and taking into account the available data, for example in an
evidence dossier, to provide decision support incorporating current uncertainty for companies
and funders. In our experience, these decision makers do make use of this decision support,
provided it takes the form of a careful, structured approach such as that described in this
paper. There are clear parallels with probabilistic risk assessment and structural reliability
modelling in engineering in the problem structure and available data.
A second interesting aspect of early clinical modelling is the standard use of care pathway
analysis in this area. This provides an informal graphical structure from which to construct
a graphical model. In this paper the model used was an influence diagram. However, with
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Query 1: Proportion of hospital admissions
Probability Probability definition
p1 Probability of having a true exacerbation when early symptoms are present
p2 Probability that a patient correctly diagnoses a true exacerbation
p3 Probability that a patient refers to SC after self-diagnosis of an exacerbation
p4 Probability that a patient refers to PC after self-diagnosis of an exacerbation
p5 Probability that a PC clinician correctly diagnoses a true exacerbation
p6 Probability that a PC clinician refers a patient to SC after an exacerbation diagnosis
p7 Probability that a SC clinician admits a patient with a true exacerbatio, if referred by PC
p8 Probability that a SC clinician admits a patient with a true exacerbation if self-referred
Table 4: Definitions of the probabilities in query 1. PC is primary care and SC is secondary
care.
other care pathways a range of graphical models could be used, such as chain event graphs,
dynamic Bayesian networks, multi-regression dynamic models, and flow graphs [Wilkerson
and Smith, 2018]. This provides a rich area of potential research for those interested in
graphical modelling. There will be similar informal graphical structures in other disciplines
which could be utilised in similar ways.
A third aspect of interest to statisticians is the link between this work and health eco-
nomics. An early economic analysis is typical in the development of clinical tests. The
graphical model developed in this paper could provide an initial structure for a health eco-
nomic analysis, by incorporating the costs, as well as the benefits, of the addition of the test
into a value node in the influence diagram. This could provide a basis, for example, for a
value of information analysis [Jalal and Alarid-Escudero, 2018, Strong et al., 2014].
Based on the analyses we carried out, we concluded that, if the diagnostic test was adopted,
we have not found any evidence that hospital admissions for true COPD exacerbations would
decrease, but we did find evidence that the number of missed exacerbations would reduce and
we also found evidence that the number of unnecessary A&E visits from COPD patients would
reduce. Further, based on the sensitivity analysis, the most influential variables were found
to be the probability that a patient would present at A&E with a suspected exacerbation
and the sensitivity of the test. These findings will inform the appropriate choice of the
target population and early adopters, and guide the refinement of the diagnostic test. These
conclusions depend on the model assumptions, especially on the structural assumptions and
on the proposed role of the test.
The modelling carried out in this paper has been static, in the sense that we have not
modelled the progression of the disease. The use of dynamic Bayesian networks or continuous
time Bayesian networks could extend the approach to incorporate this temporal progression
[Nodelman et al., 2002, Dean and Kanazawa, 1990].
The next stage of development is to finalise the device and test it in a patient population.
This will allow us to update the influence diagram with the new evidence collected, and assess
the structure of the model and inferences which we have made from it. In particular, with
observations on some of the model inputs, we would expect the uncertainty in the query
distributions to reduce, providing a clearer message, particularly for query 1.
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